DV
Dividend Vision

CRVO — CervoMed Inc.

CervoMed Inc. (CRVO)

Its deepest 1-year drawdown was 79.0%.

CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurologic disorders, with a focus on neflamapimod, an orally administered small molecule drug designed to inhibit the enzyme p38a and potentially reverse synaptic dysfunction in conditions including dementia with Lewy bodies, primary progressive aphasia, and amyotrophic lateral sclerosis. The company does not currently distribute dividends. CervoMed appeals to investors seeking exposure to early-stage biotech development rather than current income, as the company is pre-revenue and focused on advancing its pipeline toward commercialization.

CRVO key facts

Asset type
Stock
Asset class
Equity
Inception date
07/03/1996
Last close
$2.73
Market cap
$28,516,854
Average volume
606200.0
Payment date
12/14/2018
Beta
-4.421
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.28